However, regardless of the exact mechanism underlying the additional phagocytosis and trogocytosis upon treatment with CD47 antibody B6H12 specifically in SIRP-β2high AMLs, these data suggest that SIRP-β2high AML patients could significantly benefit from innate immune targeting therapies such as CD47 immune checkpoint inhibitor (ICI). This evidence concerns the gene CD47 and acute myeloid leukemia.